Valentine Wanga1, Charles Venuto, Gene D Morse, Edward P Acosta, Eric S Daar, David W Haas, Chun Li, Bryan E Shepherd. 1. aDepartments of Biostatistics bDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee cUniversity of Rochester Medical Center, Center for Human Experimental Therapeutics, Rochester dDepartment of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York eDepartment of Pharmacology and Toxicology, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama fDepartment of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California gCase Western Reserve University, Department of Epidemiology and Biostatistics, Cleveland, Ohio, USA.
Abstract
BACKGROUND:Tenofovir disoproxil fumarate (TDF) causes kidney toxicity in some patients. We carried out genomewide analyses to identify associations with plasma tenofovir clearance and change in creatinine clearance (CrCl) during the first 6 months after initiating therapy among patients randomized to TDF/emtricitabine-containing regimens in AIDS Clinical Trials Group protocol A5202. METHODS: Pharmacokinetic analyses involved 501 patients randomized to thetenofovir arm. CrCl analyses involved 1096 patients, including 548 controls randomized toabacavir-containing regimens. All had been randomized to also receive atazanavir/ritonavir or efavirenz. Multivariable linear regression and generalized least squares models were used to test for associations between polymorphisms and tenofovir clearance and CrCl change, with Bonferroni correction. Planned subanalyses considered candidate genes and polymorphisms. RESULTS:Median CrCl at baseline was 116 ml/min (interquartile range 99.8-135.5). The median change in CrCl after 6 months was -0.5 ml/min (-10.7 to +10.8) and 2.2 (interquartile range -9.9 to +13.2) in tenofovir and abacavir arms, respectively. In genomewide analyses SLC17A1 rs12662869 was found to be associated with an increase in tenofovir clearance (P=7.1×10). In candidate gene analysis for tenofovir clearance, most polymorphisms evaluated were in ABCC4. In the ABCC4 region, the lowest P-value was for CLDN10 rs12866697 (P=1.4×10). Among African Americans, SLC22A2 rs3127573 was associated with a greater 6-month CrCl increase in the tenofovir arm after correcting for multiple comparisons (P=3.3×10). CONCLUSION: Among patients randomized to receive TDF/emtricitabine in A5202, there were no significant genomewide associations with change in CrCl. This study did not replicate polymorphisms previously implicated in tenofovir-associated renal injury.
RCT Entities:
BACKGROUND:Tenofovir disoproxil fumarate (TDF) causes kidney toxicity in some patients. We carried out genomewide analyses to identify associations with plasma tenofovir clearance and change in creatinine clearance (CrCl) during the first 6 months after initiating therapy among patients randomized to TDF/emtricitabine-containing regimens in AIDS Clinical Trials Group protocol A5202. METHODS: Pharmacokinetic analyses involved 501 patients randomized to the tenofovir arm. CrCl analyses involved 1096 patients, including 548 controls randomized to abacavir-containing regimens. All had been randomized to also receive atazanavir/ritonavir or efavirenz. Multivariable linear regression and generalized least squares models were used to test for associations between polymorphisms and tenofovir clearance and CrCl change, with Bonferroni correction. Planned subanalyses considered candidate genes and polymorphisms. RESULTS: Median CrCl at baseline was 116 ml/min (interquartile range 99.8-135.5). The median change in CrCl after 6 months was -0.5 ml/min (-10.7 to +10.8) and 2.2 (interquartile range -9.9 to +13.2) in tenofovir and abacavir arms, respectively. In genomewide analyses SLC17A1rs12662869 was found to be associated with an increase in tenofovir clearance (P=7.1×10). In candidate gene analysis for tenofovir clearance, most polymorphisms evaluated were in ABCC4. In the ABCC4 region, the lowest P-value was for CLDN10rs12866697 (P=1.4×10). Among African Americans, SLC22A2rs3127573 was associated with a greater 6-month CrCl increase in the tenofovir arm after correcting for multiple comparisons (P=3.3×10). CONCLUSION: Among patients randomized to receive TDF/emtricitabine in A5202, there were no significant genomewide associations with change in CrCl. This study did not replicate polymorphisms previously implicated in tenofovir-associated renal injury.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: M R Nelson; S-A Bacanu; M Mosteller; L Li; C E Bowman; A D Roses; E H Lai; M G Ehm Journal: Pharmacogenomics J Date: 2008-02-26 Impact factor: 3.550
Authors: Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker Journal: Bioinformatics Date: 2008-10-30 Impact factor: 6.937
Authors: Sudeep P Pushpakom; Neill J Liptrott; Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Marta Albalater; Elizabeth Hopper-Borge; Stefano Bonora; Giovanni Di Perri; David J Back; Saye Khoo; Munir Pirmohamed; Andrew Owen Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Kelly Bleasby; Laura A Hall; Jennifer L Perry; Harvey W Mohrenweiser; John B Pritchard Journal: J Pharmacol Exp Ther Date: 2005-05-24 Impact factor: 4.030
Authors: Michael Horberg; Beth Tang; William Towner; Michael Silverberg; Susan Bersoff-Matcha; Leo Hurley; Joseph Chang; Jackie Blank; Charles Quesenberry; Daniel Klein Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher Journal: Clin Pharmacol Ther Date: 2007-06-27 Impact factor: 6.875
Authors: Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: Samir K Gupta; Eunice Yeh; Douglas W Kitch; Todd T Brown; Charles S Venuto; Gene D Morse; Belinda Ha; Kathleen Melbourne; Grace A McComsey Journal: J Antimicrob Chemother Date: 2017-07-01 Impact factor: 5.758
Authors: Cara Chang; Yichun Hu; Susan L Hogan; Nickie Mercke; Madeleine Gomez; Cindy O'Bryant; Daniel W Bowles; Blessy George; Xia Wen; Lauren M Aleksunes; Melanie S Joy Journal: Int J Mol Sci Date: 2017-06-22 Impact factor: 5.923
Authors: Eric H Decloedt; Phumla Z Sinxadi; Lubbe Wiesner; John A Joska; David W Haas; Gary Maartens Journal: South Afr J HIV Med Date: 2021-04-28 Impact factor: 2.744